Compare ONCO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCO | EVAX |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 31.9M |
| IPO Year | 2021 | 2020 |
| Metric | ONCO | EVAX |
|---|---|---|
| Price | $0.48 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 341.3K | 31.2K |
| Earning Date | 11-13-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $815,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.05 | $1.20 |
| 52 Week High | $7.65 | $12.15 |
| Indicator | ONCO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.03 | 54.68 |
| Support Level | $0.45 | $2.45 |
| Resistance Level | $0.95 | $6.74 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 3.33 | 52.80 |
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.